Other FDA Approved

Indium In-111 Pentetreotide

A somatostatin analog imaging agent in which the octapeptide octreotide, conjugated to the chelator DTPA, carries indium-111 to somatostatin receptor-positive cells, FDA approved since 1994 as the Octreoscan kit for scintigraphic localization of neuroendocrine tumors.

RadiopharmaceuticalSomatostatin AnalogNeuroendocrineSPECT ImagingFDA Approved

Also referenced as: Pentetreotide, Octreoscan, 111In-pentetreotide, In-111 pentetreotide, Indium In 111 pentetreotide, 111In-DTPA-octreotide, 111In-DTPA-D-Phe1-octreotide, Octreotide DTPA, SDZ 215-811

Also appears in: Hormone

Public product evidence No certificate records are bound to a tracked Indium In-111 Pentetreotide product page A record counts here only when a vendor publishes a certificate against one of its own tracked Indium In-111 Pentetreotide product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
FDA Approved

This compound maps to at least one regulated medical product or label context in the United States.

Research area
Other research areas

Primary research area: Other. Also surfaces under Hormone for browsing and discovery.

Body systems
Gut · Hormones

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
9

Pentetreotide, Octreoscan, 111In-pentetreotide, In-111 pentetreotide, Indium In 111 pentetreotide, 111In-DTPA-octreotide, 111In-DTPA-D-Phe1-octreotide, Octreotide DTPA, SDZ 215-811

Signal depth
Medium

FDA label signal · 42 trials · 805 PubMed results

Established

Indium In-111 Pentetreotide is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Indium In-111 Pentetreotide has 2 name-matched clinical trials (highest phase: Phase 4) and 805 PubMed-indexed publications and holds an FDA drug label. 1 trial has posted results.

FAERS (approved drug): 2
Human data
Approved drug
Trial quality
Randomized
Outcomes
Surrogate / early
Replication
Meta-analysis
Literature
High-impact

Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →


What is Indium In-111 Pentetreotide?

Indium In-111 pentetreotide is a radiolabeled somatostatin analog used for gamma-camera imaging. The peptide portion, pentetreotide, is octreotide with the chelator diethylenetriaminepentaacetic acid (DTPA) attached to the N-terminal D-phenylalanine, which is why the molecule is written [DTPA-D-Phe1]-octreotide or octreotide DTPA in the older literature. The cyclic octapeptide core is D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol), closed by a disulfide bond and ending in a threoninol; the Japanese regulatory review gives the unlabeled conjugate a molecular formula of C63H87N13O19S2 and a molecular weight of 1,394.60. In the kit, the DTPA arm captures indium-111, a gamma emitter with a physical half-life of 2.805 days that decays to stable cadmium-111 and emits photons at 171 and 245 keV, detected by planar scintigraphy or single-photon emission computed tomography (SPECT).

The compound was developed by Sandoz with the Rotterdam nuclear medicine group under the code SDZ 215-811 (Bakker et al., Life Sciences, 1991;49(22):1583-1591). It reached the US market as Octreoscan under NDA 020314, approved on June 2, 1994, first marketed by Mallinckrodt and now held by Curium, and it remained the standard imaging agent for neuroendocrine tumors (NETs) for two decades. Since 2016 the positron-emitting agents gallium Ga-68 dotatate, gallium Ga-68 edotreotide and copper Cu-64 dotatate have taken over most of that role. It is a diagnostic rather than a treatment, is prepared only in licensed radiopharmacies, and is absent from the research-peptide market.

How it works

  • Receptor binding by the octreotide core. Pentetreotide retains octreotide’s affinity for somatostatin receptors, which well-differentiated NETs express at high density. In the original validation work, [DTPA-D-Phe1]-octreotide bound more than 95% of added indium-111 in a single-step labeling procedure, inhibited growth hormone release from cultured rat pituitary cells like octreotide, and bound rat brain cortex membranes with nanomolar affinity (Bakker et al., Life Sciences, 1991;49(22):1583-1591). In receptor-transfected cell lines the indium-labeled DTPA conjugate had lower SSTR2 affinity than gallium-DOTA-Tyr3-octreotide, and replacing DTPA with DOTA improved SSTR3 affinity 14-fold (Reubi et al., European Journal of Nuclear Medicine, 2000;27(3):273-282).
  • Internalization and retention. After binding, the receptor-ligand complex is taken into the cell by a receptor-specific, time- and temperature-dependent process, shown for [111In-DTPA0]octreotide in SSTR2-positive rat pancreatic tumor cell lines but not in a receptor-negative line (De Jong et al., Nuclear Medicine Communications, 1998;19(3):283-288). The US label states that within an hour of injection most of the dose leaves plasma and concentrates in receptor-rich tissue, with the normal pituitary, thyroid, liver, spleen and urinary bladder also visualized in most patients.
  • Renal clearance and delayed imaging. In the first human metabolic study, the agent was cleared predominantly by the kidneys with fecal excretion of only a small fraction of the dose, the calculated effective dose equivalent was 0.08 mSv/MBq, and optimal images were obtained 24 hours after injection (Krenning et al., Journal of Nuclear Medicine, 1992;33(5):652-658). The label gives a biological half-life of 6 hours and more than 90% of the dose in urine by two days.
  • Subtherapeutic hormonal activity and receptor competition. The conjugate retains octreotide’s pharmacology, inhibiting growth hormone release from cultured rat pituitary cells (Bakker et al., Life Sciences, 1991;49(22):1583-1591), but the microgram amounts injected are far below therapeutic octreotide doses and the label puts the kit’s in vitro hormonal effect at one-tenth that of octreotide. Unlabeled octreotide or lanreotide occupies the same receptors, and 87 of the 309 evaluable approval-study patients had received therapeutic octreotide within 72 hours of imaging.

Research status

Origins in Rotterdam. The first in vivo somatostatin receptor images were obtained with 123I-labeled Tyr3-octreotide, which localized endocrine-related tumors in a small series (Krenning et al., Lancet, 1989;1(8632):242-244). That tracer required cumbersome preparation, was excreted through the liver and bowel, and used a short-lived radionuclide; the indium-111 DTPA conjugate solved all three problems (Krenning et al., Journal of Nuclear Medicine, 1992;33(5):652-658). By 1993 the Rotterdam group had imaged more than 1,000 patients, reporting that many neuroendocrine and some non-neuroendocrine tumors, as well as granulomas and autoimmune lesions, could be visualized, and that a positive scan often predicted a response to octreotide (Krenning et al., European Journal of Nuclear Medicine, 1993;20(8):716-731).

The approval studies. The US label summarizes nine unblinded studies in 365 patients aged 1.8 to 86 years with demonstrated or strongly suspected NETs, most often carcinoids, read against conventional localization by imaging, surgery or biopsy. Results were consistent with the final diagnosis in 267 of 309 evaluable patients (86.4%), with lower success for insulinomas, neuroblastomas, pituitary adenomas and medullary thyroid carcinomas than for carcinoids and gastrinomas. The scan localized previously unidentified tumors in 57 of 204 patients, but uptake also occurred in 55 of 195 patients in lesions not thought to carry somatostatin receptors. In a subgroup of 39 patients with tissue confirmation, sensitivity was 85.7% against 68% for CT/MRI, while specificity was 50% against 12%.

Clinical impact. A prospective French series of 160 patients with proven gastroenteropancreatic tumors found that scintigraphy discovered 47 new sites in 36 of 46 patients whose conventional imaging was negative, changed disease classification in 38 patients (24%) and altered the surgical strategy in 40 (25%) (Lebtahi et al., Journal of Nuclear Medicine, 1997;38(6):853-858). Procedure guidelines followed from the European Association of Nuclear Medicine (Bombardieri et al., European Journal of Nuclear Medicine and Molecular Imaging, 2010;37(7):1441-1448) and the Society of Nuclear Medicine (Balon et al., Journal of Nuclear Medicine Technology, 2011;39(4):317-324).

Gatekeeper for radionuclide therapy. The Krenning score, a four-point visual grading of tumor uptake relative to liver and spleen on planar 111In-pentetreotide images, became the eligibility criterion for peptide receptor radionuclide therapy. In the NETTER-1 trial (NCT01578239), 229 patients with progressive midgut NETs selected on this basis were randomized to lutetium Lu-177 dotatate or high-dose octreotide LAR, with estimated progression-free survival at 20 months of 65.2% versus 10.8% (Strosberg et al., New England Journal of Medicine, 2017;376(2):125-135).

Head-to-head comparisons with PET. The trials that validated its successors document its decline. In the National Cancer Institute’s prospective phase 2 study (NCT01967537), 131 patients underwent 68Ga-DOTATATE PET/CT, 111In-pentetreotide SPECT/CT and anatomic imaging; PET/CT detected 95.1% of lesions against 30.9% for pentetreotide SPECT/CT and 45.3% for anatomic imaging (Sadowski et al., Journal of Clinical Oncology, 2016;34(6):588-596). At Vanderbilt, 78 patients had both scans; 68Ga-DOTATATE PET/CT was judged equivalent or superior in every patient, changed care in 28 (36%) and correctly identified three patients for radionuclide therapy whom pentetreotide had misclassified (Deppen et al., Journal of Nuclear Medicine, 2016;57(5):708-714). A post hoc analysis of 150 patients from the NCI study showed why: receptor-expressing disease (Krenning score 2 to 4) was detected in 23% with planar pentetreotide imaging, 38% with SPECT and 72% with PET, and for lesions smaller than 2 cm the planar and SPECT detection rates fell to 15% and 24%, whereas lesions larger than 5 cm scored nearly identically (Hope et al., Journal of Nuclear Medicine, 2019;60(9):1266-1269). Multi-society appropriate use criteria placed somatostatin receptor PET ahead of scintigraphy (Hope et al., Journal of Nuclear Medicine, 2018;59(1):66-74), and in 115 Canadian patients 68Ga-DOTATOC PET raised NETTER-1 eligibility from 59.1% to 81.7% (Fedrigo et al., Neuroendocrinology, 2026;116(5):299-306).

Regulatory record. Drugs@FDA records the original approval of Octreoscan (NDA 020314) on June 2, 1994, with supplements approved December 8, 1994 and April 8, 1998 and labeling revisions approved December 22, 2021 and February 9, 2022; the application is listed as Prescription under Curium as of November 2026. A generic kit from Sun Pharmaceutical Industries (ANDA 212785) was approved on July 1, 2024 and is listed as Discontinued. In Europe the product is nationally authorized; the Irish license (PA0690/001/001, Curium Netherlands B.V.) dates from June 8, 1995. In Japan, Octreoscan Injection (Fujifilm RI Pharma) was approved on September 28, 2015 for the diagnosis of neuroendocrine tumors by somatostatin receptor scintigraphy.

Current research. As of November 2026, ClinicalTrials.gov lists no active study in which indium In-111 pentetreotide is the investigational agent; it appears only alongside PET agents in a few imaging studies, such as a recruiting phase 2 study in ectopic Cushing syndrome (NCT02019706).

Common dosage forms

  • Octreoscan kit (Curium, NDA 020314). A two-vial kit for the preparation of indium In 111 pentetreotide injection: a reaction vial containing 10 mcg of lyophilized pentetreotide and a vial of 1.1 mL indium In 111 chloride solution at 111 MBq/mL (3 mCi/mL) at calibration, supplied to licensed radiopharmacies and administered intravenously by nuclear medicine staff.
  • Indium In-111 Pentetreotide Kit (Sun Pharmaceutical Industries, ANDA 212785). A generic kit of the same 3 mCi/mL strength, approved in 2024 and listed as discontinued.
  • Octreoscan 111 MBq/mL kit (Europe) and Octreoscan Injection (Japan). The nationally authorized two-vial kit for radiopharmaceutical preparation with 10 mcg of pentetreotide.

Key considerations

  • Regulatory status. The FDA Approved status reflects the June 2, 1994 approval of Octreoscan, a kit for the preparation of indium In 111 pentetreotide injection, under NDA 020314, held by Curium and listed as Prescription. The only generic, the Sun Pharmaceutical Industries kit under ANDA 212785 approved July 1, 2024, is listed as discontinued, and the US indication is limited to scintigraphic localization of receptor-bearing neuroendocrine tumors.
  • Largely superseded by PET. Gallium-68 and copper-64 somatostatin analogs detect roughly three times as many lesions, miss far fewer tumors under 2 cm, deliver results the same day rather than at 24 hours and have been preferred by appropriate use criteria since 2018. Indium In-111 pentetreotide remains relevant where PET is unavailable and as the reference method for the NETTER-1 Krenning score.
  • A localization tool with known blind spots. Uptake depends on receptor density, so insulinomas, neuroblastomas, pituitary adenomas and medullary thyroid carcinomas were localized less often than carcinoids and gastrinomas in the approval studies, while granulomas and other receptor-expressing tissues can produce uptake that is not a NET; in the only tissue-confirmed subgroup of the approval studies, specificity was 50%.
  • Safety signals. Adverse effects in the clinical trials occurred in less than 1% of 538 patients and were transient; postmarketing reports are dominated by hypersensitivity reactions, mostly rash and pruritus, with rare angioedema or features of anaphylaxis. The label warns of severe hypoglycemia in patients with insulinoma because pentetreotide is an octreotide analog, and the agent adds to cumulative radiation exposure, with the kidneys, spleen and bladder wall receiving the highest absorbed doses.
  • Naming. Pentetreotide (USAN and JAN), octreotide DTPA, [DTPA-D-Phe1]-octreotide, SDZ 215-811, 111In-pentetreotide and Octreoscan all denote the same molecule, which is distinct from octreotide itself and from the DOTA-conjugated agents dotatate and edotreotide despite the shared octreotide core.